BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26947960)

  • 1. Impact of novel histopathological factors on the outcomes of liver surgery for colorectal cancer metastases.
    Serrablo A; Paliogiannis P; Pulighe F; Moro SS; Borrego-Estella V; Attene F; Scognamillo F; Hörndler C
    Eur J Surg Oncol; 2016 Sep; 42(9):1268-77. PubMed ID: 26947960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphological aspects of the hepatic response to neoadjuvant therapy.
    Fernández-Aceñero MJ; Cortés-Guiral D; Muñoz LE; Martínez-Useros J; Pastor-Idoate C
    Pathol Res Pract; 2015 Sep; 211(9):665-70. PubMed ID: 26163186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nomogram predicted disease free survival for colorectal liver metastasis patients with preoperative chemotherapy followed by hepatic resection.
    Liu W; Wang K; Han Y; Liang JY; Li YH; Xing BC
    Eur J Surg Oncol; 2019 Nov; 45(11):2070-2077. PubMed ID: 31279595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases.
    Berardi G; De Man M; Laurent S; Smeets P; Tomassini F; Ariotti R; Hoorens A; van Dorpe J; Varin O; Geboes K; Troisi RI
    Eur J Surg Oncol; 2018 Jul; 44(7):1069-1077. PubMed ID: 29615295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases.
    Brandi G; Derenzini E; Falcone A; Masi G; Loupakis F; Pietrabissa A; Pinna AD; Ercolani G; Pantaleo MA; Di Girolamo S; Grazi GL; de Rosa F; Biasco G
    Clin Colorectal Cancer; 2013 Sep; 12(3):188-94. PubMed ID: 23773458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognosis of liver resection for patients with four or more colorectal liver metastases has not improved in the era of modern chemotherapy.
    Hokuto D; Nomi T; Yamato I; Yasuda S; Obara S; Yoshikawa T; Kawaguchi C; Yamada T; Kanehiro H; Nakajima Y
    J Surg Oncol; 2016 Dec; 114(8):959-965. PubMed ID: 27683191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study.
    Malik H; Khan AZ; Berry DP; Cameron IC; Pope I; Sherlock D; Helmy S; Byrne B; Thompson M; Pulfer A; Davidson B
    Eur J Surg Oncol; 2015 Apr; 41(4):499-505. PubMed ID: 25703078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
    Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases.
    Miller CL; Taylor MS; Qadan M; Deshpande V; Worthington S; Smalley R; Collura C; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Parikh AR; Berger D; Tanabe KK; Lillemoe KD; Ferrone CR
    J Gastrointest Surg; 2017 Nov; 21(11):1831-1840. PubMed ID: 28884391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study).
    Hatano E; Okuno M; Nakamura K; Ishii T; Seo S; Taura K; Yasuchika K; Yazawa T; Zaima M; Kanazawa A; Terajima H; Kaihara S; Adachi Y; Inoue N; Furumoto K; Manaka D; Tokka A; Furuyama H; Doi K; Hirose T; Horimatsu T; Hasegawa S; Matsumoto S; Sakai Y; Uemoto S
    J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):634-45. PubMed ID: 25926024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases.
    Dexiang Z; Li R; Ye W; Haifu W; Yunshi Z; Qinghai Y; Shenyong Z; Bo X; Li L; Xiangou P; Haohao L; Lechi Y; Tianshu L; Jia F; Xinyu Q; Jianmin X
    Ann Surg Oncol; 2012 Sep; 19(9):2860-8. PubMed ID: 22526903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Choice of surgical strategy for colorectal liver metastases depending on clinical and pathological response to neoadjuvant chemo- and targeted therapy].
    Jakab F
    Orv Hetil; 2010 Nov; 151(47):1956-60. PubMed ID: 21071308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study.
    Aloysius MM; Zaitoun AM; Beckingham IJ; Neal KR; Aithal GP; Bessell EM; Lobo DN
    Virchows Arch; 2007 Nov; 451(5):943-8. PubMed ID: 17805566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy.
    Tamandl D; Klinger M; Eipeldauer S; Herberger B; Kaczirek K; Gruenberger B; Gruenberger T
    Ann Surg Oncol; 2011 Feb; 18(2):421-30. PubMed ID: 20844968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety evaluation of simultaneous resection of colorectal primary tumor and liver metastasis after neoadjuvant therapy: A propensity score matching analysis.
    Wu Y; Liu F; Song W; Liang F; Wang L; Xu Y
    Am J Surg; 2019 Nov; 218(5):894-898. PubMed ID: 30268420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
    Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
    World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.
    Yi JH; Kim H; Jung M; Shin SJ; Choi JS; Choi GH; Baik SH; Min BS; Kim NK; Ahn JB
    Oncology; 2013; 85(5):283-9. PubMed ID: 24217184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined portal vein embolization and preoperative chemotherapy prior to liver resection for colorectal cancer metastases.
    Spelt L; Norman P; Törnqvist L; Tingstedt B; Andersson R
    Scand J Gastroenterol; 2012 Sep; 47(8-9):975-83. PubMed ID: 22631611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Graf A; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Ann Surg Oncol; 2015 Apr; 22(4):1315-23. PubMed ID: 25323471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.